TPTX insider filings
Turning Point Therapeutics, Inc. — 48 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-08-17. Screen TPTX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for TPTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Turning Point Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-08-17 | 4 | Nicholson Garry A — Director | Disposition to issuer (D): 23,400 (derivative) · Disposition to issuer (D): 8,500 (derivative) | EDGAR |
| 2022-08-17 | 4 | Bodem Barbara W. — Director | Disposition to issuer (D): 14,995 (derivative) | EDGAR |
| 2022-08-17 | 4 | TOMBESI PAOLO — EVP & Chief Financial Officer | Disposition to issuer (D): 29,778 @ $76 · Disposition to issuer (D): 61,200 (derivative) · Disposition to issuer (D): 58,600 (derivative) | EDGAR |
| 2022-08-17 | 4 | Sun Brian — SVP & General Counsel | Disposition to issuer (D): 45,000 @ $76 · Disposition to issuer (D): 195,000 (derivative) | EDGAR |
| 2022-08-17 | 4 | Sabus Steve M — SVP & Chief Commercial Officer | Disposition to issuer (D): 36,667 @ $76 · Disposition to issuer (D): 165,000 (derivative) | EDGAR |
| 2022-08-17 | 4 | Hirmand Mohammad — EVP and Chief Medical Officer | Disposition to issuer (D): 41,284 @ $76 · Disposition to issuer (D): 169,192 (derivative) · Disposition to issuer (D): 29,175 (derivative) · Disposition to issuer (D): 68,367 (derivative) | EDGAR |
| 2022-08-17 | 4 | George Simeon — Director | Disposition to issuer (D): 2,253,660 @ $76 · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 8,500 (derivative) · Disposition to issuer (D): 8,500 (derivative) | EDGAR |
| 2022-08-17 | 4 | Countouriotis Athena — President & CEO, Director | Disposition to issuer (D): 110,959 @ $76 · Disposition to issuer (D): 173,389 (derivative) · Disposition to issuer (D): 67,575 (derivative) · Disposition to issuer (D): 989,971 (derivative) · Disposition to issuer (D): 155,844 (derivative) · Disposition to issuer (D): 325,000 (derivative) · +2 more | EDGAR |
| 2022-08-17 | 4 | Alles Mark J — Director | Disposition to issuer (D): 2,000 @ $76 · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 209 (derivative) | EDGAR |
| 2022-08-17 | 4 | Gallagher Carol Giltner — Director | Disposition to issuer (D): 8,500 (derivative) · Disposition to issuer (D): 8,500 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2022-08-17 | 4 | Machado Patrick — Director | Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 8,500 (derivative) · Disposition to issuer (D): 8,500 (derivative) | EDGAR |
| 2022-07-29 | 4 | TOMBESI PAOLO — EVP & Chief Financial Officer | Sale (S): 1,183 @ $74.94 | EDGAR |
| 2022-06-01 | 4 | Sabus Steve M — SVP & Chief Commercial Officer | Grant/award (A): 36,667 @ $0 · Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2022-04-12 | 4 | Sun Brian — SVP & General Counsel | Grant/award (A): 45,000 @ $0 · Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2022-02-11 | 4 | TOMBESI PAOLO — EVP & Chief Financial Officer | Grant/award (A): 16,283 @ $0 · Grant/award (A): 58,600 (derivative) @ $0 | EDGAR |
| 2022-02-11 | 4 | Partridge Andrew John — EVP & Chief Commercial Officer | Sale (S): 221 @ $36.30 · Grant/award (A): 16,283 @ $0 · Grant/award (A): 58,600 (derivative) @ $0 | EDGAR |
| 2022-02-11 | 4 | Hirmand Mohammad — EVP & Chief Medical Officer | Sale (S): 669 @ $36.30 · Grant/award (A): 18,983 @ $0 · Grant/award (A): 15,000 @ $0 · Grant/award (A): 68,367 (derivative) @ $0 | EDGAR |
| 2022-02-11 | 4 | Countouriotis Athena — President & CEO, Director | Sale (S): 2,971 @ $36.30 · Grant/award (A): 62,400 @ $0 · Grant/award (A): 224,640 (derivative) @ $0 | EDGAR |
| 2022-02-11 | 4 | Reich Siegfried — EVP & Chief Scientific Officer | Sale (S): 397 @ $36.30 · Grant/award (A): 13,567 @ $0 · Grant/award (A): 48,833 (derivative) @ $0 | EDGAR |
| 2022-02-11 | 4 | North Annette — EVP & General Counsel | Sale (S): 669 @ $36.30 · Grant/award (A): 16,283 @ $0 · Grant/award (A): 58,600 (derivative) @ $0 | EDGAR |
| 2021-08-31 | 4 | North Annette — EVP, General Counsel & Secty. | Option exercise (M): 10,000 @ $17 · Sale (S): 10,000 @ $80 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2021-07-27 | 4 | TOMBESI PAOLO — EVP & Chief Financial Officer | Grant/award (A): 13,600 @ $0 · Grant/award (A): 61,200 (derivative) @ $0 | EDGAR |
| 2021-07-15 | 4 | Partridge Andrew John — EVP & Chief Commercial Officer | Sale (S): 1,869 @ $74.90 | EDGAR |
| 2021-06-21 | 4 | Alles Mark J — Director | Purchase (P): 2,000 @ $81.34 | EDGAR |
| 2021-06-16 | 4 | North Annette — EVP, General Counsel & Secty. | Option exercise (M): 15,000 @ $17 · Sale (S): 5,666 @ $75.94 · Sale (S): 2,700 @ $77.37 · Sale (S): 6,634 @ $77.82 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Nicholson Garry A — Director | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | George Simeon — Director | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Alles Mark J — Director | Grant/award (A): 209 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Gallagher Carol Giltner — Director | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Machado Patrick — Director | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2021-05-26 | 4 | Alles Mark J — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2021-05-07 | 4 | North Annette — EVP, General Counsel & Secty. | Option exercise (M): 5,882 @ $17 · Option exercise (M): 5,882 (derivative) @ $0 | EDGAR |
| 2021-04-01 | 4 | Bodem Barbara W. — Director | Grant/award (A): 14,995 (derivative) @ $0 | EDGAR |
| 2021-03-24 | 4 | Baker Brian Lee — SVP of Finance and Admin. | Grant/award (A): 1,625 @ $0 · Option exercise (M): 11,904 @ $2.19 · Option exercise (M): 1,298 @ $3.20 · Option exercise (M): 4,545 @ $5.12 · Option exercise (M): 10,688 @ $7.43 · Sale (S): 4,919 @ $97.89 · +10 more | EDGAR |
| 2021-03-09 | 4 | North Annette — EVP, General Counsel & Secty. | Option exercise (M): 20,000 @ $17 · Sale (S): 500 @ $103.30 · Sale (S): 4,810 @ $109.09 · Sale (S): 9,419 @ $109.89 · Sale (S): 4,571 @ $110.77 · Sale (S): 700 @ $111.69 · +1 more | EDGAR |
| 2021-03-05 | 4 | Reich Siegfried — EVP & Chief Scientific Officer | Option exercise (M): 35,550 @ $51.28 · Sale (S): 3,005 @ $102.01 · Sale (S): 8,820 @ $102.87 · Sale (S): 6,220 @ $103.65 · Sale (S): 2,000 @ $104.97 · Sale (S): 3,103 @ $105.71 · +6 more | EDGAR |
| 2021-02-11 | 4 | Countouriotis Athena — President & CEO, Director | Option exercise (M): 18,000 @ $3.20 · Option exercise (M): 7,666 @ $3.20 · Sale (S): 6,200 @ $136.29 · Sale (S): 103 @ $137.58 · Sale (S): 4,969 @ $138.66 · Sale (S): 13,290 @ $139.69 · +15 more | EDGAR |
| 2021-02-10 | 4 | Hirmand Mohammad — EVP and Chief Medical Officer | Grant/award (A): 6,483 @ $0 · Grant/award (A): 29,175 (derivative) @ $0 | EDGAR |
| 2021-02-10 | 4 | Partridge Andrew John — EVP & Chief Commercial Officer | Grant/award (A): 2,136 @ $0 · Grant/award (A): 9,733 (derivative) @ $0 | EDGAR |
| 2021-02-10 | 4 | Larson Yi — EVP & Chief Financial Officer | Grant/award (A): 4,617 @ $0 · Grant/award (A): 20,775 (derivative) @ $0 | EDGAR |
| 2021-02-10 | 4 | Baker Brian Lee — SVP of Finance and Admin. | Grant/award (A): 1,483 @ $0 · Grant/award (A): 6,675 (derivative) @ $0 | EDGAR |
| 2021-02-10 | 4 | Countouriotis Athena — President & CEO, Director | Grant/award (A): 22,617 @ $0 · Grant/award (A): 101,775 (derivative) @ $0 | EDGAR |
| 2021-02-10 | 4 | Reich Siegfried — EVP & Chief Scientific Officer | Grant/award (A): 3,845 @ $0 · Grant/award (A): 17,303 (derivative) @ $0 | EDGAR |
| 2021-02-10 | 4 | North Annette — EVP, General Counsel & Secty. | Grant/award (A): 6,483 @ $0 · Grant/award (A): 29,175 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Larson Yi — EVP & Chief Financial Officer | Option exercise (M): 15,702 @ $54.03 · Sale (S): 4,783 @ $122.94 · Sale (S): 8,576 @ $123.70 · Sale (S): 2,143 @ $124.60 · Sale (S): 200 @ $126.07 · Option exercise (M): 14,298 @ $54.03 · +7 more | EDGAR |
| 2021-02-02 | 4 | North Annette — EVP, General Counsel & Secty. | Option exercise (M): 15,984 @ $17 · Sale (S): 1,630 @ $122.58 · Sale (S): 10,541 @ $123.49 · Sale (S): 3,313 @ $124.41 · Sale (S): 500 @ $125.38 · Option exercise (M): 9,016 @ $17 · +8 more | EDGAR |
| 2021-01-08 | 4 | Baker Brian Lee — SVP of Finance and Admin. | Option exercise (M): 11,905 @ $2.19 · Option exercise (M): 1,299 @ $3.20 · Option exercise (M): 4,545 @ $5.12 · Option exercise (M): 10,689 @ $7.43 · Sale (S): 2,800 @ $122.65 · Sale (S): 900 @ $120.16 · +7 more | EDGAR |
| 2021-01-05 | 4 | Hirmand Mohammad — EVP and Chief Medical Officer | Option exercise (M): 8,747 @ $54.73 · Sale (S): 300 @ $122.44 · Sale (S): 8,747 @ $120.42 · Option exercise (M): 1,253 @ $54.73 · Sale (S): 1,253 @ $120 · Option exercise (M): 8,747 (derivative) @ $0 · +1 more | EDGAR |
Recent 8-K events — Turning Point Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2022-08-17 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-08-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-06-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2022-06-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2022-06-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-06-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-05-10 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-05-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2022-04-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TPTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs